Cardiac Imaging News

Ultrasound Useful for Early Detection of Lung Congestion in Dialysis …

Italian researchers have found that ultrasound can be used in the early detection of fluid in dialysis patients' lungs, which could prevent the development of fatal heart problems. The researchers, led by Carmine Zoccali, M.D., director of the nephrology, hypertension and renal transplantation unit at Riuniti Hospital in Reggio Calabria, reported the results of their study online in the Journal of the American Society of Nephrology. Patients who undergo dialysis for ... Read more

Infraredx Appoints Michael Guarasci as Chief Financial …

BURLINGTON, Mass. – December 23, 2012 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the appointment of Michael Guarasci as chief financial officer. Mr. Guarasci joins Infraredx with more than 25 years of experience in financial operations and investment management, and will be responsible for the overall financial strategy and operations for the company. He will report to Donald Southard, president and chief executive officer. “We are very pleased to welcome Mike to Infraredx as a member of the executive leadership team,” said Mr. Southard. “Mike’s knowledge of the capital markets, in-depth management and financial expertise will be a tremendous asset to the company. We look forward to working closely with him as we continue to execute our corporate business strategy and lay the foundation for our next phase of growth.” Mr. Guarasci is a seasoned financial executive with extensive experience in strategic planning, operations, investment management and information technology. He joins Infraredx from Indus Capital Partners LLC, where he was chief operating officer, responsible for leading the company’s day-to-day financial operations and overseeing the firm’s senior management committee. Prior to Indus, Mr. Guarasci held leadership positions at the Credit Suisse U.S. Asset Management division, serving as a managing director and chief financial officer. In this role, he helped lead the $100 billion investment management firm through the integration of Warburg Pincus Asset Management, Garantia Asset Management in Brazil and a handful of additional small acquisitions throughout his six-year tenure at the firm. Mr. Guarasci holds a Bachelor of Science from the Rochester Institute of Technology and a Masters in Business Administration from the State University of New York at Buffalo. “I am eager to help Infraredx continue to optimize its business strategy and pursue opportunities related to the TVC Imaging System™,” said Mr. Guarasci. “There is a growing need for intravascular imaging technologies that improve the management and treatment of patients with coronary artery disease. This is a very exciting time for the company as it continues to experience accelerated demand for the TVC Imaging System, driven by the increased recognition of the need to accurately characterize vessels to better detect lipid core plaques that are prone to cause stenting-related complications.” About Infraredx, Inc. Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stenting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com. Contacts: Grant Frazier Vice President of Marketing Infraredx, Inc.781-345-9632gfrazier@infraredx.com Susan Heins (media) Pure Communications, Inc. 864-286-9597 ... Read more

Liverpool Heart and Chest Hospital Expands Cardiac …

MAGNETOM Aera installation supports specialist hospital’s demand for increased cardiac MR imaging Liverpool Heart and Chest Hospital NHS Foundation Trust has expanded its cardiac MR imaging capabilities with the installation of a MAGNETOM® Aera 1.5 Tesla MRI system from Siemens Healthcare. The system’s deployment follows the installation of a Siemens SOMATOM® Definition Flash CT system earlier in the year. The Aera has helped to reduce patient waiting times by providing increased capacity for cardiac imaging. It has also enhanced patient comfort resulting in reduced claustrophobia. The MAGNETOM Aera 1.5T system features a 70cm Open Bore and short system for enhanced patient comfort, while its advanced post-processing abilities automate a number of processes to assist workflow and maintain excellent image quality. Furthermore, the system’s implementation of Tim 4G (Total imaging matrix) and Dot™ (Day optimising throughput) technology, together with 48 channels and lightweight coils, ensures flexible and comprehensive exam strategies. “The MAGNETOM Aera and SOMATOM Definition Flash installations represent a new relationship with Siemens Healthcare for Liverpool Heart and Chest Hospital. The feedback we have received from staff on the quality of images from both systems has been excellent,” states Janette Rekatas, Radiology Manager at Liverpool Heart and Chest Hospital. “The Aera’s installation has enabled us to develop and expand our cardiac imaging capabilities at the hospital. Patient feedback has been very positive since the installation – the open bore and short system design has led to a significantly reduced rate of claustrophobia, increasing efficiency and patient throughput in the process.” “The Definition Flash system has been praised by staff for its excellent image quality, fast scanning times and low dose,” Janette Rekatas adds. “The Siemens MRI and CT installations have greatly assisted in extending the provision for cardiac imaging at Liverpool Heart and Chest Hospital,” states John Brady, Regional Sales Manager at Siemens Healthcare. “It is fantastic to hear of the dramatic reduction in patient claustrophobia since the Aera’s deployment, thanks to its short footprint and wide Open Bore design, resulting in shorter patient examination times. This design asset combined with the integrated Tim and Dot technology enables the system to improve workflow within the department.” About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. For further information please visit: http://www.siemens.co.uk/healthcare. For more information or images please contact: Marc Gossage / Jon WilcoxMedia SafariT: 01225 471202E: jonw@mediasafari.co.uk Siemens HealthcareLaura BennettT: 01276 696374E: laura.bennett@siemens.comW: ... Read more

Infraredx Announces TVC Imaging System to be …

BURLINGTON, Mass. – October 20, 2012 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be highlighted in 10 poster and oral presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2012). TCT 2012, the world's largest educational meeting specializing in interventional cardiovascular medicine, will be held October 22-26, 2012 at the Miami Beach Convention Center in Miami. The TVC Imaging System is a first-in-class intravascular imaging system with the unique ability to assess vessel composition and structure via integrated near infrared spectroscopy (NIRS) lipid core plaque (LCP) detection and enhanced intravascular ultrasound (IVUS) imaging technology. The TVC Imaging System is the only device available in both the U.S. and Europe for the detection of the LCPs known to complicate stenting and believed to be the reason for most heart attacks. Outside of the U.S., the TVC Imaging System is available in more than 30 countries worldwide. “We are pleased that our TVC Imaging System is being prominently featured at the leading educational meeting in interventional cardiovascular medicine,” said Donald Southard, president and chief executive officer of Infraredx. “There is a growing awareness of and need for the TVC Imaging System as more than two million people worldwide undergo coronary stenting each year, pointing to the clinical advantages of characterizing vessel structure and composition. We look forward to sharing this new data at TCT highlighting the value of the TVC Imaging System in at-risk patient populations.” The company will be exhibiting at booth #667 during the conference. The schedule of oral and poster presentations, as well as the breakfast satellite symposium, is as follows: Oral Presentations The TVC Imaging System will be a subject of discussion in a series of oral presentations, including: •    On Tuesday, October 23 at 1:50 p.m., James E. Muller, M.D., founder, chairman and chief medical officer of Infraredx, will participate in a session titled “The Great Vulnerable Plaque Debate: Is Vulnerable Plaque a Systemic or Focal Disease?” where he will engage in a debate with Valentin Fuster, M.D., The Mount Sinai Hospital, in a presentation titled “Most Diseases Are Systemic: It’s the Focal Manifestations That Count!” This presentation will be held in Room B212-213. •    On Tuesday, October 23 at 4 p.m., Ryan D. Madder, M.D., Frederik Meijer Heart & Vascular Institute, Spectrum Health System in Grand Rapids, Michigan, will discuss the TVC Imaging System in a presentation titled “NIRS as a Clinical Tool for Vulnerable Plaque Detection: Findings in Patients with Acute STEMI.” This presentation will be held in Room B212-213. Moderated Poster Presentation The TVC Imaging System will be a subject of discussion in the following poster presentations: Presentation Date/Time: Tuesday, October 23, 8-10 a.m.Session Title: Detection of Thin and Thick Fibrous Caps Overlying Lipid Core Coronary Plaques with a Catheter-Based Near-Infrared Spectroscopy SystemPresenter: Sean Madden, Ph.D., Senior Scientist, InfraredxNumber/Location: Abstract #1924, Hall D Oral Abstracts: Adjunct Imaging and Physiology Session The TVC Imaging System will be a subject of discussion in a series of oral presentations, including:Presentation Date/Time: Tuesday, October 23, 12 – 12:15 p.m.Session Title: Detection by Near-infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients with Acute ST-Segment Elevation Myocardial InfarctionPresenter: Ryan D. Madder, M.D., Frederik Meijer Heart & Vascular Institute, Spectrum Health System in Grand Rapids, MichiganNumber/Location: Abstract #TCT-23, Room#D239 NOTE: Please note that this abstract has also been selected for video wall viewing all day on Wednesday, October 24, outside the Main Arena where TCT attendees can review these oral abstracts at their leisure. Presentation Date/Time: Thursday, October 25, 2-3 p.m.Session Title: Yellow Means Trouble: Challenging Case Session V: Imaging and Physiologic Lesion Assessment and Structural SessionPresenter: David Erlinge, M.D., Ph.D., Lund University Hospital in Lund, Sweden Number/Location: Abstract#1292, Hall D Breakfast Symposium Infraredx will host a satellite symposium titled “Identifying the Signature of STEMI Culprit Plaques with Near IR Spectroscopy: What Does It Mean For Your Practice?” The 60-minute breakfast panel event will be held on Thursday, October 25 at 7 a.m. in Room #C225/226. The symposium will be chaired by James A. Goldstein, M.D., director of research and education, division of cardiology, William Beaumont Hospital; discussants include Ryan D. Madder, M.D., Frederik Meijer Heart & Vascular Institute, Spectrum Health System in Grand Rapids, Michigan and David Erlinge, M.D., Ph.D., Lund University Hospital in Lund, Sweden. About The TVC Imaging System™ The TVC Imaging System™ is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The device enables cardiologists to predict peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid core plaques (LCP) of interest. In a single pullback, the TVC Imaging System provides rapid and automated detection of LCPs during the cardiac catheterization procedure. The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure, in real time. The system’s enhanced IVUS image provides a clear view of the vessel and plaque, providing more reliable vessel interpretation and assessment. The system’s NIRS technology enables interventional cardiologists to reliably visualize the presence of LCP and predict the risk of peri-stenting myocardial infarction. The multimodality images are obtained simultaneously and require no post-processing or image manipulation. The TVC Imaging System is the only device available in both the U.S. and Europe for the detection of LCPs. Outside of the U.S., the TVC Imaging System is available in more than 30 countries worldwide. About Infraredx, Inc. Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stenting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com. Contacts: Infraredx Grant Frazier Vice President of Marketing Infraredx, Inc.781-345-9632gfrazier@infraredx.comSusan Heins (media) Pure Communications, Inc. 864-286-9597 ... Read more

Siemens Delivers Advanced Cardiovascular CT Training …

Four day course hosted to offer hands-on training, analysis of cardiac CT data sets including post-percutaneous coronary intervention and surgery assessment skills Siemens Healthcare, in partnership with the British Institute of Radiology (BIR), hosted a successful four day advanced cardiovascular CT training course for imaging professionals. For the first time, the course was held at the Siemens Academy training and education centre. It was developed to provide delegates with the case volume, formal teaching and the firm understanding of best cardiovascular CT practice required for advanced cardiovascular CT training. It was also suited to those working towards BSCI / SCCT accreditation in cardiovascular CT. The course provided access to 150 cases to develop delegates’ analytical CT skills and supplied representative cases of non-coronary disease including congenital heart disease, pre-ablation assessment and Transcatheter Aortic Valve Implantation (TAVI) assessment. 17 recorded cases were also provided, allowing interactive discussion. Short didactic teaching sessions on pathology and related technologies were also provided for delegates. An optional additional 25 in-room participation cases were facilitated through attendance at Royal Brompton Hospital and King’s College Hospital after the course. “We provide an intensive, comprehensive course designed to give increased confidence when independently reporting cardiovascular CT scans,” stated Dr Ed Nicol, Course Director and Consultant Cardiologist at Royal Brompton and Harefield NHS Foundation Trust. “Delegates benefit from expert instruction and learn in detail about cardiovascular CT, cardiology and the detection of cardiovascular disease with CT.” “Delegates attending this course were provided with in-depth training to deal with common problems encountered within routine CT practice,” commented Russell Lodge, CT Business Manager at Siemens Healthcare. “Attendees were also trained to systematically and effectively assess cardiac CT data sets, covering all major pathology groups including normal anatomy, anatomical variants, CT angiography, atherosclerotic CAD, as well as post PCI and post surgery assessment. We are confident that this successful course will be repeated and that it was a valuable and enjoyable learning experience for all involved.” The course was run by cardiothoracic radiologists and cardiologists with extensive experience of cardiovascular CT; the faculty has published many articles, chapters and books on numerous aspects of cardiovascular CT and its role in cardiac and coronary disease. The advanced cardiovascular CT training courses are suited to delegates that are performing cardiac imaging on any suitable CT platform and prior experience on Siemens syngo®.via or CT scanners is not expected. For information about future Siemens Healthcare courses being run in conjunction with BIR, please email sarah.cowan@siemens.com [1] This course offers the chance to study up to 150 cardiac cases. It is not a prerequisite that the course is 'Level II' About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. For further information please visit: http://www.siemens.co.uk/healthcare. About British Institute of Radiology (BIR) The British Institute of Radiology is an independent multidisciplinary organisation, and a registered charity, whose membership is open to everyone with an interest in radiology and radiation oncology. For further information please visit: www.bir.org.uk For more information or images please contact: Siemens HealthcareLaura BennettT: 01276 696374E: laura.bennett@siemens.comW: http://www.siemens.co.uk/healthcare Thomas O’Neill / Marc GossageMedia SafariT: 01225 471202E: ... Read more

Freeman Hospital to Take Imaging to The Next Level …

Hospital orders SOMATOM Definition Flash from Siemens Healthcare with new Stellar Detector technology for enhanced image quality, rapid imaging and low dose benefits Freeman Hospital, part of the Newcastle upon Tyne Hospitals NHS Foundation Trust, has ordered a SOMATOM® Definition Flash CT system from Siemens Healthcare. The state-of-the-art system, due to be installed later this year, replaces a previous-generation Siemens four-slice CT system. Selected for its image quality, rapid scan times and low dose capabilities, it will be used for a range of procedures including cardiac CT, paediatric scanning, coronary angiography and general imaging. The Definition Flash is a Dual Source CT system with Spiral Dual Energy where two X-ray sources run simultaneously at different energies, acquiring two data sets showing different attenuation levels for easy classification of the scanned tissue. Diagnostic confidence is enhanced, assisting the clinician to make sustainable and sound treatment decisions in daily practice. The hospital will also be using the Dual Source system for advanced oncology research such as quantifying tumour perfusion and its response to chemotherapy. Freeman Hospital will be one of the first to benefit from the new Stellar Detectors from Siemens, designed to dramatically reduce electronic noise, cross-talk and increase the signal-to-noise ratio. This ensures slice blurring between neighbouring detector rows can be avoided and results in a much more precise imaging process. The system also has two adaptive dose shields to ensure that patients only receive the minimum, clinically relevant dose and can reduce dose values down to one millisievert or less. The heart can be examined at a radiation exposure level that is three times lower than the background radiation a person naturally absorbs in a year. “With an international reputation for pioneering treatment in many areas including transplant surgery, it was important for us to select a CT system that would future-proof our imaging services ” said Graeme Hughes, Senior Superintendent Radiographer / Manager at Freeman Hospital. “We decided to go for the gold standard in Dual Energy imaging, which can provide us with pre- and post-contrast images in a single scan. The added benefits of low dose and rapid scan times, particularly in paediatric CT, will also alleviate our anaesthetic specialists’ workload.” “We look forward to helping Freeman Hospital benefit from state-of-the-art imaging, it will be one of the first to receive the new Stellar Detector,” said Neil Lincoln, Northern Sales Manager at Siemens Healthcare. “In addition to an existing CT system from Siemens Healthcare, the Definition Flash will help support the busy clinical environment at the hospital, plus provide the speed and excellent image quality needed for an accurate and confident diagnosis.” About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. For further information please visit: http://www.siemens.co.uk/healthcare. For more information or images please contact: Siemens HealthcareLaura BennettT: 01276 696374E: laura.bennett@siemens.comW: http://www.siemens.co.uk/healthcare Marc Gossage / Thomas O’NeillMedia SafariT: 01225 471202E: ... Read more

Six Spire Healthcare Hospitals Broaden CT Services to …

Mobile SOMATOM Definition AS combined with syngo.via ‘thin client’ server from Siemens Healthcare enabling six private hospitals to offer cardiac CT imaging and reporting to patients for the first time Private healthcare provider Spire Healthcare has deployed a mobile SOMATOM® Definition AS CT system from Siemens Healthcare, adding specialist CT imaging capabilities to six Spire hospitals located across the north-west and north-east of England and north Wales. The system offers high resolution imaging with reduced dose for clinical efficiency and enhanced patient care, allowing those Spire hospitals to offer cardiology CT scans at new locations. The system is further supported with the syngo®.via advanced visualisation application from Siemens Healthcare, which has enabled the hospitals to avoid investing in workstations at individual sites. It is being used as a ‘thin client’ centralised server shared between the six hospitals, streamlining the process of sharing information between the mobile unit and the sites. The use of syngo.via has enabled radiologists to access images for evaluation from other locations, which has encouraged quick and accurate diagnoses and decision making. The six sites benefitting from the new mobile SOMATOM Definition AS CT scanner are Spire Fylde Coast Hospital in Blackpool; Spire Liverpool Hospital; Spire Yale Hospital in Wrexham; Spire Elland Hospital in Halifax; Spire Murrayfield Hospital Wirral; and Spire Hull and East Riding Hospital. The mobile SOMATOM Definition AS enables the hospitals to offer patients a broad range of CT imaging capabilities in-situ, including 3D orthopaedic imaging, CT colonography and routine oncology, neurology and cardiac imaging. The system allows for high-speed whole body coverage at a high spatial resolution, while its wide aperture and load capacity minimises patient exclusion. Additionally, the use of FAST CARE technology in the Definition AS rationalises workflow and ensures patients receive the lowest dose possible. “The SOMATOM Definition AS from Siemens Healthcare represents reliable CT imaging, helping improve clinical efficiency and patient care through reduced dose and outstanding image quality,” said Dianne Hopkins, Head of Mobile Imaging at Spire Healthcare. “Since its recent launch by Spire, feedback has been very positive; patients have commented on the unit’s enhanced clinical environment which makes for a very comfortable imaging experience.” “The mobile SOMATOM Definition AS together with syngo.via has enabled Spire Healthcare to expand its CT services in the north west and east of England, plus north Wales,” said Vince Golledge, Regional Sales & Corporate Business Manager at Siemens Healthcare. “The system’s deployment has already received positive patient feedback and broadens the services available in new geographic regions.” About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare. For more information or images please contact: Siemens HealthcareLaura BennettT: 01276 696374E: laura.bennett@siemens.comW: http://www.siemens.co.uk/healthcare Marc Gossage / Jon WilcoxMedia SafariT: 01225 471202E: ... Read more

Tetralogy of Fallots Case Wins CT Image Award…

Great Ormond Street Hospital takes home prize for best image quality and lowest radiation dose using Siemens Healthcare’s SOMATOM Definition CT scanner Carol Young, Radiographer at Great Ormond Street Hospital for Children NHS Foundation Trust has won the Siemens Healthcare International CT Image Contest in the Cardiac category for her ‘Tetralogy of Fallots’ case. The image, which was captured on a Siemens Healthcare SOMATOM® Definition scanner, was chosen for its image quality and obtained using the lowest radiation dose. The 2011 awards announced at the end of the year received 627 submissions from over 43 countries, and the entries were judged by a jury of eight internationally renowned radiology professors. The image was announced and exhibited at RSNA 2011 and has earned Great Ormond Street Hospital an exclusive ‘Siemens Low Dose Expert’ seal. The SOMATOM Definition DS is a first generation Dual Source CT system that uses two X-ray sources and two detectors at the same time to provide double the temporal resolution, twice the speed and power while lowering the dose. The SOMATOM Definition allows any heart and heart rate to be scanned without the need of beta-blockers at a low radiation dose. Speaking on the case win for Great Ormond Street Hospital for Children, Radiographer Carol Young states, “I was both happy and surprised to hear that I had been nominated for my Tetralogy of Fallot image, which showed the four defects including connection between the ventricles and the absence of the pulmonary valve. Hearing that I had won was a real honour – every radiology professional strives to achieve best diagnostic quality at the lowest possible dose. Particularly in paediatric imaging it is crucial to minimise the associated radiation risks, as children are more sensitive to radiation exposure.” “The SOMATOM Definition scanner is ideal for paediatric imaging – not just for the unusual congenital conditions such as this Tetralogy of Fallot case, but across a wide range of procedures and we wonder what Carol would have achieved with the latest higher performing ‘Flash’ dual source system,” states Russell Lodge, CT Business Manager at Siemens Healthcare. “We are delighted that a long-term UK Siemens customer has received acclaim in the international image contest with over 600 entries.” About Great Ormond Street Hospital: Great Ormond Street Hospital was the first children’s hospital and only the fourth UK centre to get Imaging Services Accreditation Scheme (ISAS) accreditation. About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare. Great Ormond Street Hospital was the first children’s hospital and only the 4th UK centre to get ISAS accreditation. (Imaging Services Accreditation Scheme) For more information or images please contact: Charlotte Rowland / Thomas O’Neill Media Safari T: 01225 471202 E: charlotter@mediasafari.co.uk Siemens Healthcare Laura Bennett T: 01276 696374 E: laura.bennett@siemens.com W: ... Read more

Infraredx Announces TVC Imaging System to be …

Company’s First-in-Class Intravascular Technology for True Vessel Characterization to be Featured During Cardiovascular Innovations Educational Forum BURLINGTON, Mass. – March 21, 2012 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be featured in 11 oral and poster presentations, including a panel during the Cardiovascular Innovations Educational Forum, at the American College of Cardiology 61st Annual Scientific Session & Expo (ACC.12) and ACC-i2 with TCT, being held March 24-27, 2012, at the McCormick Place Convention Center in Chicago. The TVC Imaging System is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The system’s improved image resolution delivers better clinical detail, providing more reliable vessel interpretation and assessment. The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). “We are pleased to present important new information on the TVC Imaging System at the ACC.12 meeting,” said James E. Muller, M.D., founder, chairman and chief medical officer of Infraredx. “Our IVUS image provides a high quality view of structures – vessel diameter, stent expansion – and our NIR data, obtained in the same pullback, provides accurate, automated detection of lipid core plaque. New data to be presented show that the versatile spectroscopy method can identify cap thickness as well as lipid core detection, and a comparison with non-invasive CTA shows the potential of CTA to serve as a screening tool for lipid core plaque. A potential screening strategy employing new technology will be featured in a special session in the Exposition Hall.” The company will be exhibiting at booth #3054 during the conference. The schedule of oral and poster presentations at ACC.12 and ACC-i2 with TCT, including a panel during the Cardiovascular Innovations Educational Forum, is as follows: Cardiovascular Innovations Educational Forum On Sunday, March 25 at 3:55 p.m., Dr. James Muller will discuss the TVC Imaging System in a presentation titled “The Role of Invasive Imaging with IVUS, NIR, and OCT to Confirm the Presence of Vulnerable Plaques” during the panel discussion “The Role of Innovative Technologies in a Novel Strategy to Prevent First Coronary Event.” The panel, which is part of the Cardiovascular Innovations Educational Forum, will be held in Hall A2 of the CV Theater. Case Sessions On Saturday, March 24 from 2-5 p.m., the TVC Imaging System will be a subject of discussion during the “Live and Taped Case Session I: Multivessel PCI- Physiology and Imaging” session, being held during the i2 Live and Taped Cases (Session #2201) in Hall B of the ACC.12 Main Tent. The session will be chaired by Gary S. Mintz, M.D., chief medical officer, Cardiovascular Research Foundation. Dr. Mintz will give a presentation titled “The Exploding World of Intravascular Imaging: IVUS, OCT, NIRS, etc - Practical Use during PCI” (Presentation #2201-13) from 3:45 to 4 p.m. Emmanouil S. Brilakis, M.D., Ph.D., director, Cardiac Catheterization Laboratories, VA North Texas Health Care System, and associate professor of medicine, The University of Texas Southwestern Medical Center at Dallas, will present a taped case utilizing the TVC Imaging System from the University of Texas Southwestern Medical Center (Presentation #2201-15) from 4:15 to 5 p.m. Oral Presentations The TVC Imaging System will be a subject of discussion in a series of oral presentations, including: Presentation Date/Time:     Saturday, March 24, 4:30-6 p.m.Session Title:     Intravascular Imaging: Restenosis, Thrombosis and Stent Follow-up II: Very Late Stent Thrombosis and Late Catch-upPresenter:     Co-chaired by Evelyn Regar, M.D., Ph.D., associate professor, department of interventional cardiology, Thoraxcenter, Erasmus MCSession Type/Location:    i2 Symposium, Presentation #2611-2, Room S101A Presentation Date/Time:     Sunday, March 25, 8-8:10 a.m.Presentation Title:     Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content? Results From: Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy (YELLOW) TrialSession Title:    Intravascular DiagnosticsPresenter:     Annapoorna Subhash Kini, M.D., MRCP, FACC, associate director, Cardiac Cath Lab, Mt. Sinai Hospital        Session Type/Location:     i2 Oral Contributions, Presentation #2508-6, Room S106B Presentation Date/Time:    Sunday, March 25, 8:45-8:55 a.m.Presentation Title:    Coronary Computed Tomographic Angiography Morphologic Characteristics of Lipid-core Plaques Identified by Intracoronary Near-Infrared SpectroscopySession Title:            Intravascular Diagnostics Presenter:            James L. Smith, M.D., William Beaumont Hospital    Session Type/Location:    i2 Oral Contributions, Presentation #2508-11, Room S106B Presentation Date/Time:    Sunday, March 25, 9-9:10 a.m.Presentation Title:    Spectroscopic Detection of Fibrous Cap Thickness Overlying Lipid Core Coronary Plaques with a Catheter-Based Near-Infrared Spectroscopy SystemSession Title:            Intravascular Diagnostics Presenter:            Sean Madden, Ph.D., director of systems engineering, Infraredx        Session Type/Location:    i2 Oral Contributions, Session #2508-13, Room S106B Presentation Date/Time:     Monday, March 26, 10:30 a.m.-noon (Session); 10:40-10:50 a.m. (Presentation)Presentation Title:     Optical Coherence Tomography and Near-Infrared SpectroscopySession Title:    Establishing a Cardiac Catheterization Imaging/Physiology ProgramPresenter:     Session co-chaired and presentation given by Emmanouil S. Brilakis, M.D., Ph.D., director, Cardiac Catheterization Laboratories, VA North Texas Health Care System and associate professor of medicine, The University of Texas Southwestern Medical Center at DallasSession Type/Location:    i2 Symposium, Session #2629-2 (Session) and #2629-4 (Presentation), Room S101A Presentation Date/Time:     Monday, March 26, 4:30-4:40 p.m.Presentation Title:     Distal Embolization during PCI: Predicting Distal Embolization Using Grayscale IVUS, RF-IVUS, OCT, and NIRSSession Title:    Controversies in Intravascular ImagingPresenter:     Emmanouil S. Brilakis, M.D., Ph.D., director, Cardiac Catheterization Laboratories, VA North Texas Health Care System, and associate professor of medicine, The University of Texas Southwestern Medical Center at DallasSession Type/Location:     i2 Symposium, Presentation #2639-10, Room S101A Poster Presentations Presentation Date/Time:     Saturday, March 24, 9:30-10:30 a.m.Session Title:    Intravascular DiagnosticsPoster Discussant:     Emmanouil S. Brilakis, M.D., Ph.D., director, Cardiac Catheterization Laboratories, VA North Texas Health Care System, and associate professor of medicine, The University of Texas Southwestern Medical Center at DallasSession Type/Location:     i2 Poster Contributions, Presentation #2527-2, Hall A Presentation Date/Time:     Sunday, March 24, 9:30 a.m.-noonPresentation Title:     In Vivo Lipid Core Plaque Burden and Spatial Distribution in Patients with Unstable Angina and NQMI: A Near-Infrared Spectroscopy StudySession Title:    Intravascular DiagnosticsPresenter:     Brijeshwar Singh Maini, M.D., FACC, chair, Structural Heart Program, and co-chair, cardiovascular research, Pinnacle Health SystemSession Type/Location:     i2 Poster Contributions, Session #2527-549, Hall A Presentation Date/Time:     Monday, March 26, 9:30-10:30 a.m.Presentation Title:     Distribution of Lipid Core Rich Plaques in Coronary Bifurcations Assessed by Near-Infrared SpectroscopySession Title:    New Tools for Invasive Evaluation of the Coronaries: What Else Can I See?Presenter:     Jung Ho Heo, M.D., Kosin University Gospel Hospital, Busan KoreaSession Type/Location:     ACC Moderated Poster Contributions, Presentation #1203-299, Hall A About TVC Imaging System™ The TVC Imaging System™ is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The TVC system enables cardiologists to predict peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid core plaques (LCP) of interest. In a single pullback, the TVC Imaging System provides rapid and automated detection of LCPs during the cardiac catheterization procedure. The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure in real time. The system’s enhanced IVUS image provides a clear view of the vessel and plaque, providing more reliable vessel interpretation and assessment. The system’s NIRS technology enables interventional cardiologists to reliably visualize the presence of LCP and predict the risk of peri-stenting myocardial infarction. The multimodality images are obtained simultaneously and require no post-processing or image manipulation. The TVC Imaging System is the only device approved by the U.S. Food and Drug Administration for the detection of LCP. About Infraredx, Inc. Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease.  The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stenting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com. Contacts: Susan Heins (media) Pure Communications, Inc. 864-286-9597 sjheins@purecommunicationsinc.com Grant Frazier Vice President of Marketing Infraredx, Inc. ... Read more

New Market Research Highlight the Combined Use of …

According to Kalorama Information, a leading healthcare market research publisher, ultrasound and MRI systems become more effective when combined with each other. Other useful information was discussed in a recent report titled “Medical Imaging Markets: MRI and Ultrasound”. It was mentioned that the global revenues for MRI grew by 6% between 2010 and 2011. Ultrasound systems, on the other hand, witnessed growth by 4% during the same period. Among the examples of ultrasound and MRI combinations is rotator cuff. In this example, ultrasound is considered more cost effective while MRI is more used for elevating the rotator cuff. During a revision of a cost utility analysis, it was found that using ultrasound as a starting medical imaging test for a rotator cuff tear, followed by a pre-operative MRI to determine the disease or disorder, can be very powerful and effective mixed imaging plan. Joe Constance, Kalorama's imaging analyst and the author of the report, said "Ultrasound is a cheaper imaging modality, yet MRI can provide more depth. So it's not a surprise to see ultrasound recommended for the initial medical imaging test and an MRI as a secondary test to find any alternate diagnosis and give the surgeon the needed anatomy." The report also discussed another issue, which is using combination of imaging modalities in breast cancer. It was mentioned that using breast ultrasound along with MRI helps in identification of lesions that sometimes are not identified with mammography. In addition, ultrasound can be used as a starting procedure to determine if a certain lesion is malignant or benign. This approach became accepted following a study that took place at the University of Rome La Sapienza, Rome, ... Read more

FluoroPharma Medical Announces Phase II Study for …

Company Advances First in Class Diagnostic Agent for the Detection and Assessment of Acute and Chronic Forms of Coronary Disease That Affects Millions of Patients Worldwide BOSTON, March 1, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, announces today that the company has recruited SGS Life Science Services as the CRO for their Phase II study of CardioPET to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients has started. CardioPET, one of FluoroPharma's first in class PET imaging products, is a perfusion and fatty acid uptake indicator, which may be used as a cardiac imaging agent that may be an accurate alternative to standard treadmill stress-testing. This could be especially valuable in patients who are unable to exercise. The phase II trial will be an open label trial designed to assess the safety and diagnostic performance of CardioPET as compared to stress echocardiography, myocardial perfusion imaging and angiography as a gold standard of background disease. Two trial sites are planned in Belgium and results are expected in the second half of 2012. Thijs Spoor, President and Chief Executive Officer of FluoroPharma Medical, added: "We are delighted to announce SGS Life Science Services as the CRO for this phase II trial; a significant milestone for FluoroPharma and our extraordinary pipeline of products. Symptomatic coronary artery disease (CAD) affects millions of patients worldwide and accounts for a significant and increasing percentage of all deaths. It is clear that novel diagnostic imaging agents are urgently required and we are focused on driving forward the development of our pipeline to meet these needs. Commenting on the announcement, David Elmaleh, Chief Scientific Officer of FluoroPharma Medical said, "We are very excited to be initiating this Phase II study for CardioPET. CardioPET's differentiated and superior imaging profile could have a significant impact on the evaluation of CAD patients across the spectrum of disease severity. Because CardioPET can detect perfusion and fatty acid uptake insufficiency in the myocardium; CardioPET could potentially be an accurate alternative to stress-testing in patients with CAD." About CardioPET CardioPET is a modified fatty acid (MFA) that closely resembles naturally-occurring free fatty acids (FFAs) in the human body. FFAs are the major source of energy for healthy myocardium, where they are transported into the mitochondria and are then metabolized via beta-oxidation. CardioPET has completed Phase I studies where it was well tolerated and did not induce any adverse events or clinically significant deviations in laboratory values. The total radiation exposure was minimal and well within safety limits. About Coronary Artery Disease (CAD) According to the American Heart Association more than 12 million people alive today have a history of heart attack, angina pectoris (chest pain) or both. The American Heart Association also estimates that 1,100,000 Americans will have a new or recurrent coronary attack this year – one-third of these patients will die making coronary artery disease the single leading cause of death in America today. About FluoroPharma Medical FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston. FluoroPharma's goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes. The Company's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers. For more information on the Company, please visit: www.fluoropharma.com. Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact: Mission Investor Relations 3645 Marketplace Blvd. Suite 130-280 Atlanta, GA ... Read more

Foetal Cardiology Course Gives Delegates Confidence to …

Siemens Healthcare supports the development and education of cardiac professionals Birmingham Women’s Hospital, part of Birmingham Women’s NHS Foundation Trust, recently hosted a two-day long foetal cardiology course, supported by Siemens Healthcare. The sessions were designed for obstetricians, radiologists, radiographers and pediatric cardiologists with the main objective to increase knowledge and confidence to identify and manage abnormal foetal cardiac anatomy using ultrasound. Delegates from both the host hospital and further afield attended the course, including international representation. The ACUSON S2000™ diagnostic ultrasound system from Siemens Healthcare was demonstrated via a video link from the Foetal Medicine Department to assist with practical real-time study discussions of abnormal cardiac scans. Delegates attended a variety of lectures ranging from foetal heart anatomy and pathology to midline cardiac anomalies. Lecturers included Professor Lindsey Allan of King’s College Hospital and Professor Mark Kilby of Birmingham Women’s Hospital, allowing delegates to gain in-depth knowledge and engage directly with foetal cardiology experts. “The content of the course was excellent and the lectures were very informative,” stated Ruth Brookes, Advanced Practitioner Sonographer at The Dudley Group NHS Foundation Trust, a delegate on the course. “It was particularly helpful to be able to visualise the moving cardiac images on ultrasound, as opposed to the traditional use of static slides. The case discussion focussing on abnormalities in first trimester cardiac scanning provided valuable information and insight. I have recommended this course to my colleagues and we very much hope it is one which will be run again.” “The foetal cardiology course held at Birmingham Women’s Hospital has proved to be a great success,” commented Bernadette Leonard, Regional Sales Manager and Clinical Applications Manager at Siemens Healthcare. “Delegates were guided through the latest advances and applications to increase knowledge of the foetal cardiac scanning and pathology. This educational course was well-received by delegates and we are confident it is one which will be repeated.” About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare. For more information or images please contact: Marc Gossage / Thomas O’Neill Media Safari T: 01225 471202 E: thomaso@mediasafari.co.uk Siemens Healthcare Laura Bennett T: 01276 696374 E: laura.bennett@siemens.com W: ... Read more


 …

The NHS National Institute for Health and Clinical Excellence (NICE) has published guidance approving NHS use of new generation scanners to help diagnose and manage patients with coronary artery disease (CAD) who are difficult to image. The guidance, which was prompted by Siemens proffering its SOMATOM® Definition Flash dual source scanner for evaluation, draws evidence from 24 published papers of which 20 cited use of Siemens dual source scanners. Dual source CT remains unique to Siemens scanners, and utilizes two X-ray sources and two banks of detectors. Such developments have enabled continuous improvement of spatial and temporal resolution to optimize visualization within the coronary vessel, whilst also driving down radiation dose. Peter Harrison, Divisional Director of Imaging at Siemens Healthcare states, “The NICE guidance is a welcome approval of new generation CT scanners, and I am delighted that it draws evidence from so many experiences of Siemens Dual Source scanners. The guidance is not intended to be a comparison report, especially as Dual Source CT is still unrivalled and unique to the market.” Siemens innovations within cardiac CT build upon the high end single source Definition AS+, launched at Radiological Society of North America (RSNA) 2008. This system, with a large bore of 78cm and increased tube rotation speed delivers a full rotation within 0.3 seconds. This provided temporal resolution down to 150ms, quick enough to freeze the cardiac motion on a wider range of patients – essential to complement the spatial resolution affording clarity of intra vascular detail, whilst delivering very low dose. These two parameters working in combination have driven Siemens’ global installed base of new generation Cardiac CT scanners beyond 1,750 systems. The further development of Dual Source scanners such as the SOMATOM Definition Flash offer still greater flexibility of examination techniques to avoid patient exclusions, not only in cardiac imaging but in all fields of CT imaging, such as paediatric and trauma imaging. Ever mindful of patient dose, Peter Harrison continues, “Dual sources do not necessitate increased dose. In over 64,000 cardiac ‘Flash’ exams we continue to experience an average radiation dose of 0.85mSv. Moreover, Siemens’ latest iterative reconstruction (SAFIRE) which boasts FDA-approved dose potential of up to 60% adds additional patient safety without compromising the high image quality of the 128 slice z-Sharp acquisition.” Deepa Gopalan, Consultant Cardiovascular Radiologist at Cambridge University Hospitals NHS Foundation Trust states, “Whilst dose reduction continues to be important, cardiac CT today is also about ease of use of both the scanner and the evaluation of the images. The combination of the Siemens scanner and the new syngo.via platform move cardiac imaging into a new dimension in terms of speed and confidence.” Siemens continues to innovate and launched its new Stellar detector at RSNA 2011. This revolution in detector design fully integrates the electronic components in a manner that virtually eliminates electronic noise. Peter Harrison adds, “This will continue to push the boundaries of cardiac imaging with ultra thin slices delivering very high spatial resolution for unprecedented levels of visual detail. The new detector is also designed to optimize ultra low signal imaging which is invaluable for obese and paediatric patients, and dual energy applications.” The Stellar Detector is expected to be available from summer 2012 and will be available within the SOMATOM Definition Flash Dual Source scanner, as well as single source systems such as the SOMATOM Definition Edge (also announced at RSNA 2011). About Siemens Healthcare The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare. For more information or images please contact: Georgina Wright / Marc Gossage Media Safari T: 01225 471202 E: marcg@mediasafari.co.uk Siemens Healthcare Laura Bennett T: 01276 696374 E: laura.bennett@siemens.com W: ... Read more

Page 5 of 15

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.
javporn.cc